The role of RAS modification for primary and secondary stroke prevention

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Clinical trial results indicate that the choice of antihypertensive agent can be a determinant of stroke protection, independent of blood pressure (BP) reduction. Angiotensin-converting enzyme inhibitors (ACE-Is) are effective for BP control and stroke protection, but their use may be limited by patient tolerability. Angiotensin receptor blockers appear to provide similar BP control compared with ACh-Is and may also offer the clinician the added benefit of primary and secondary stroke prevention, with the potential for fewer tolerability issues.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalPostgraduate Medicine
Issue number4
StatePublished - Jul 1 2009


  • Angiotensin 2 type 1 receptor blockers
  • Angiotensin-converting enzyme inhibitors
  • Hypertension
  • Renin-angiotensin system
  • Stroke

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The role of RAS modification for primary and secondary stroke prevention'. Together they form a unique fingerprint.

Cite this